ArticleNPJ precision oncology2025

Plasma proteomic biomarkers predict therapeutic responses in advanced biliary tract cancer patients receiving Camrelizumab plus the GEMOX treatment.

Shiyun Cui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.